Clinical Trial

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Protocol Amendment History 29 amendments
This ClinicalTrials.gov record has been amended 29 times since 2019-08-22; most recent amendment 2026-06-19.
Trial Details
NCT Number NCT04068597
Lead Sponsor CellCentric Ltd.
Conditions Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
Enrollment 250 participants
Start Date 2019-08-09
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-24